MUSCULAR DYSTROPHY ASSOCIATION, INC. for MUSCULAR DYSTROPHY ASSOCIATION, INC.
What was lobbied
12 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Testified in front of the ACHDNC on newborn screening Prepared efforts for reauthorization of the Newborn Screening Saves Lives Reauthorization Act Encouraged action on telehealth legislation to the Energy and Commerce Committee Supported H.R. 7623, the Telehealth Modernization Act of 2024 Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act: Supported the ALS Better Care Act Provided comments to Energy and Commerce Committee on Medicaid access Advocated for the protection of the Medicaid program to the White House and Congress Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act Supported H.R. 7384, Creating Hope Reauthorization Act of 2024 Supported the amended Give Kids a Chance Act Supported the MINI Act Supported the NIH Clinical Trial Diversity Act Supported H.R. 4758, Accelerating Kids Access to Care Act Supported the Access to Genetic Counseling Services Act Advocated for provisions addressing problems within the pharmacy benefit manager industry Supported the introduction of legislation that amends the anti-kickback statute to allow companies to cover the costs of traveling to obtain therapies Supported robust funding for NCATS Supported robust funding for NIAMS Filed comments, and joined coalition comments, on the Consumer Financial Protection Bureau Proposed Medical Debt Rule Filed comments to the FDA on the Platform Technology Designation Program for Drug Development Guidance for Industry Joined Coalition Comments to the Contract Year 2025 Medicare Physician Fee Schedule Proposed Rule Joined Coalition Comments in Support of the Think Differently Database Act Testified in front of an FDA CBER Patient Listening Session Filed comments to FDA in Response to Diversity Action Plan Guidance Prepared for the reauthorization of the ACT for ALS
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Aviation/Airlines/Airports AVI
Joined coalition comments on the role of AI in assisting those with disabilities in transportation Joined Coalition Comments to the Department of Transportation Urging Finalization of the Wheelchair User Experience Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Budget/Appropriations BUD
Supported enhanced funding for NCATS, NIAMS, and the entire NIH Supported robust appropriations for the newborn screening program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Retirement RET
Joined coalition comments on the process the Social Security Administration takes in requesting additional information Supported the SSI Savings Penalty Elimination Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD | — |
Taxation/Internal Revenue Code TAX
Supported the ENABLE Act, legislation to better amplify the importance of ABLE accounts
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL MELMEYER | — |
| SHANNON WOOD | — |
Medical/Disease Research/Clinical Labs MED
Testified in front of the ACHDNC on newborn screening Prepared efforts for reauthorization of the Newborn Screening Saves Lives Reauthorization Act Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act Supported H.R. 7384, Creating Hope Reauthorization Act of 2024 Supported the amended Give Kids a Chance Act Supported the NIH Clinical Trial Diversity Act Supported robust funding for NCATS Filed comments to the FDA on the Platform Technology Designation Program for Drug Development Guidance for Industry Testified in front of an FDA CBER Patient Listening Session Filed comments to FDA in Response to Diversity Action Plan Guidance Prepared for the reauthorization of the ACT for ALS
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
Medicare/Medicaid MMM
Supported the ALS Better Care Act Advocated for the protection of the Medicaid program to the White House and Congress Supported the MINI Act Supported H.R. 4758, Accelerating Kids Access to Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Encouraged action on telehealth legislation to the Energy and Commerce Committee Supported H.R. 7623, the Telehealth Modernization Act of 2024 Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act: Supported the Access to Genetic Counseling Services Act Joined Coalition Comments to the Contract Year 2025 Medicare Physician Fee Schedule Proposed Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Insurance INS
Supported H.R. 7623, the Telehealth Modernization Act of 2024 Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act: Supported the ALS Better Care Act Advocated for the protection of the Medicaid program to the White House and Congress Supported H.R. 4758, Accelerating Kids Access to Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Access to Genetic Counseling Services Act Advocated for provisions addressing problems within the pharmacy benefit manager industry Joined Coalition Comments to the Contract Year 2025 Medicare Physician Fee Schedule Proposed Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Pharmacy PHA
Encouraged action on telehealth legislation to the Energy and Commerce Committee Supported H.R. 7623, the Telehealth Modernization Act of 2024 Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act: Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act Supported H.R. 7384, Creating Hope Reauthorization Act of 2024 Supported the amended Give Kids a Chance Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Advocated for provisions addressing problems within the pharmacy benefit manager industry Supported the introduction of legislation that amends the anti-kickback statute to allow companies to cover the costs of traveling to obtain therapies Testified in front of an FDA CBER Patient Listening Session Prepared for the reauthorization of the ACT for ALS Filed comments to the FDA on the Platform Technology Designation Program for Drug Development Guidance for Industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOEL CARTNER | — |
| PAUL MELMEYER | — |
| SHANNON WOOD | — |
Transportation TRA
Joined coalition comments on the role of AI in assisting those with disabilities in transportation Joined Coalition Comments to the Department of Transportation Urging Finalization of the Wheelchair User Experience Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Education EDU
Supported the RISE Act Supported the Full Funding is the Right IDEA Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL MELMEYER | — |
| SHANNON WOOD New | — |
Civil Rights/Civil Liberties CIV
Joined coalition comments on online systems to assist disabled voters in the voting registration process
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL MELMEYER | — |
| SHANNON WOOD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.